Results from a phase I proof-of-mechanism study with a vasopressin 1A receptor antagonist in autism spectrum disorder

被引：0
|
作者：
Rubido, M. Del Valle [1 ]
Umbricht, D. [1 ]
Shic, F. [2 ]
McCracken, J. T. [3 ]
Scahill, L. [4 ]
Khwaja, O. [1 ]
Squassante, L. [5 ]
Boak, L. [1 ]
Bolognani, F. [1 ]
Fontoura, P. [6 ]
Wall, C. [2 ]
Jou, R. [2 ]
Loomis, R. [2 ]
Lyons, M. [2 ]
Gavaletz, A. [2 ]
Cowen, J. [3 ]
Apelian, T. [3 ]
Jeste, S. [3 ]
Ferretti, C. [7 ]
Taylor, B. [7 ]
Berlin, G. [7 ]
Noone, R. [7 ]
Antar, L. [7 ]
Hollander, E. [7 ]
机构：
[1] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Translat Med NORD, Basel, Switzerland
[2] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA
[3] Univ Calif Los Angeles, Semel Inst, CAN Clin, Psychiat & Biobehav Sci, Los Angeles, CA USA
[4] Emory Univ, Marcus Autism Ctr, Atlanta, GA 30322 USA
[5] F Hoffmann La Roche Ltd, Prod Dev Biometr, Basel, Switzerland
[6] F Hoffmann La Roche Ltd, Prod Dev Neurosci, Basel, Switzerland
[7] Albert Einstein Coll Med, Psychiat, New York, NY USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2015年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.7.d.011
引用
收藏
页码：S646 / S647
页数：2
相关论文
共 50 条
  • [1] Erratum: A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder
    Daniel Umbricht
    Marta del Valle Rubido
    Eric Hollander
    James T McCracken
    Frederick Shic
    Lawrence Scahill
    Jana Noeldeke
    Lauren Boak
    Omar Khwaja
    Lisa Squassante
    Christophe Grundschober
    Heidemarie Kletzl
    Paulo Fontoura
    Neuropsychopharmacology, 2017, 42 : 1924 - 1924
  • [2] A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder (vol 42, pg 1914, 2017)
    Umbricht, Daniel
    Rubido, Marta del Valle
    Hollander, Eric
    McCracken, James T.
    Shic, Frederick
    Scahill, Lawrence
    Noeldeke, Jana
    Boak, Lauren
    Khwaja, Omar
    Squassante, Lisa
    Grundschober, Christophe
    Kletzl, Heidemarie
    Fontoura, Paulo
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 (09) : 1924 - 1924
  • [3] Discovery of Balovaptan, a Vasopressin la Receptor Antagonist for the Treatment of Autism Spectrum Disorder
    Schnider, Patrick
    Bissantz, Caterina
    Bruns, Andreas
    Dolente, Cosimo
    Goetschi, Erwin
    Jakob-Roetne, Roland
    Kuennecke, Basil
    Mueggler, Thomas
    Muster, Wolfgang
    Parrott, Neil
    Pinard, Emmanuel
    Ratni, Hasane
    Risterucci, Celine
    Rogers-Evans, Mark
    von Kienlin, Markus
    Grundschober, Christophe
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (04) : 1511 - 1525
  • [4] Discovery of RG7314: A vasopressin 1a receptor antagonist for the treatment of social communication deficits in autism spectrum disorders
    Schnider, Patrick
    Biemans, Barbara
    Bissantz, Caterina
    Dolente, Cosimo
    Goetschi, Erwin
    Jakob-Roetne, Roland
    Muster, Wolfgang
    Parrott, Neil
    Pinard, Emmanuel
    Ratni, Hasane
    Risterucci, Celine
    Rogers-Evans, Mark
    Schmitt, Monique
    Grundschober, Christophe
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [5] A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder
    Bolognani, Federico
    Rubido, Marta del Valle
    Squassante, Lisa
    Wandel, Christoph
    Derks, Michael
    Murtagh, Lorraine
    Sevigny, Jeff
    Khwaja, Omar
    Umbricht, Daniel
    Fontoura, Paulo
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (491)
  • [6] A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD
    Lijffijt, Marijn
    Green, Charles E.
    Balderston, Nicholas
    Iqbal, Tabish
    Atkinson, Megan
    Vo-Le, Brittany
    Vo-Le, Bylinda
    O'Brien, Brittany
    Grillon, Christian
    Swann, Alan C.
    Mathew, Sanjay J.
    FRONTIERS IN PSYCHIATRY, 2019, 10
  • [7] Association Testing of Vasopressin Receptor 1a Microsatellite Polymorphisms in Non-Clinical Autism Spectrum Phenotypes
    Procyshyn, Tanya L.
    Hurd, Peter L.
    Crespi, Bernard J.
    AUTISM RESEARCH, 2017, 10 (05) : 750 - 756
  • [8] V1a Antagonist (RG7713) Proof of Mechanism Study in High Functioning Autism Spectrum Disorder: Clinical, Biomarker and Social Learning Effects
    Hollander, Eric
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S63 - S63
  • [9] Affective Speech Recognition Clinical Biomarker Effects of a Novel Vasopressin 1a Receptor Antagonist Vs Placebo in Adult Autism
    Hollander, Eric
    Rubido, Marta del Valle
    Khwaja, Omar
    Squassante, Lisa
    Ferretti, Casara J.
    Taylor, Bonnie P.
    Berlin, Gregory
    Noone, Rachel
    Antar, Laura
    McCracken, James
    Scahill, Lawrence
    Shic, Frederick
    Umbricht, Daniel
    BIOLOGICAL PSYCHIATRY, 2014, 75 (09) : 324S - 325S
  • [10] Assessing and stabilizing atypical plasticity in autism spectrum disorder using rTMS: Results from a proof-of-principle study
    Desarkar, Pushpal
    Rajji, Tarek K.
    Ameis, Stephanie H.
    Blumberger, Daniel M.
    Lai, Meng-Chuan
    Lunsky, Yona
    Daskalakis, Zafiris J.
    CLINICAL NEUROPHYSIOLOGY, 2022, 141 : 109 - 118
12345